


INTRODUCTION

1,3-Butadiene



- 1,3-Butadiene (1,3-BD) is a petroleum-derived volatile organic compound
- 36th highest volume chemical produced in the United States
- Primarily used for production of synthetic rubber (tires, resins, and plastics)

- Emitted from combustion sources:
 - Automobile Exhaust
 - Tobacco Smoke
 - Wood Fires
- OSHA limits: 1ppm over 8 hours, 5ppm over 15-minute period

- In Humans:**

 - Hematopoietic cancers in workers^{1,2}
 - Cardiovascular disease risk³
 - vascular dysfunction⁴
 - biomarkers of cardiopulmonary injury & oxidative stress⁵

Animal Studies:

 - Multi-organ tumorigenesis^{3,6,7}
 - e.g., lung, liver, hematopoietic, mammary, & reproductive
 - Exacerbation of atherosclerosis⁸




Figure 1: Potential mechanisms of 1,3-BD-induced Cardiovascular Injury

Hypothesis: 1,3-BD exposure increases epithelial barrier permeability & upregulates genes involved in pulmonary inflammatory and oxidative stress pathways, which may extend systemically to cardiovascular injury.

METHODS

Air-liquid interface (ALI) may provide a more physiologically relevant approach for modelling human inhalation exposures *in vitro*.


Figure 2: *In vitro* methods of exposure

- Human bronchial epithelial cells (BEAS-2B) cultured for ~21 days.
- Media removed from apical surface to create ALI conditions.
- Generation & delivery of 1,3-BD (2%v/v) aerosol cloud via Vitrocell® cloud system.
- Following exposure, cells were placed in fresh media for 24 hours.
- Transepithelial electrical resistance (TEER) measured to assess epithelial barrier integrity.
- Media & cells collected to evaluate cytotoxicity & gene expression.
- Messenger RNA sequencing (mRNA-seq) performed via Novogene Inc. to identify differentially expressed genes (DEGs) & pathways.


*n=3 independent experiments, each with n=6 technical replicates per group.

RESULTS

Figures 3 & 4: 1,3-butadiene reduced TEER of the cell monolayer (1.5-fold) without causing overt cell death.




*Mean ± SEM, *P<0.05, **P<0.01.



*%LDH normalized to positive control.

Figure 5: 1,3-BD exposure significantly upregulates mRNA expression of *GREM1* & *SERPINB2*.



GREM1 – Bone morphogenic protein (BMP) antagonist

- Linked to inflammation, fibrosis, & several cancers
- High expression → poor prognosis in cancers^{9,10}
- Stimulates PI3K/AKT signaling pathway¹¹ → epithelial-mesenchymal transition (EMT)

SERPINB2 – Plasminogen activator inhibitor-2 (PAI-2)

- Inhibitor of cell proliferation & migration
- Low expression → reduced survival in lung adenocarcinomas¹² (independent prognostic factor)

Figures 7 & 8: GO & Reactome Enrichment Analyses indicate 1,3-BD exposure is associated with early oncogenic responses

Figure 7: Go Enrichment Analysis



Figure 8a: Reactome Enrichment Analysis




Fig. 8b ReactomePA-UP




Fig. 8c dotplot for ReactomePA-UP





Figure 6: KEGG Enrichment Analysis reveals involvement of ribosome biogenesis & PI3K/AKT signaling pathway.




*Promotes tumor cell proliferation & survival

*Critical regulator of epithelial-mesenchymal transition (EMT) in lung cancers.

CONCLUSION

1,3-BD exposure may promote carcinogenesis in human bronchial epithelial cells (BEAS-2B) by activating *GREM1* to potentiate epithelial-mesenchymal transition (EMT) through stimulation of the PI3K/AKT signaling pathway. Overexpression of *SERPINB2* may serve as an initial protective mechanism to reduce cell migration & EMT.



ACKNOWLEDGEMENTS

This study is supported by NIEHS grant P42ES023716, T32-ES011564, K.C. Donnelly externship supplemental grant, and in collaboration with Louisiana State University Superfund Research Project (P42ES013648).

REFERENCES

- Delzell et al (1996), Toxicology, 113.
- Macaluso et al (1996), Toxicology, 113.
- ATSDR (1992).
- McGraw et al (2021), Environmental Research, 196.
- Lin et al (2020), Journal of Hazardous Materials, 396.
- U.S. EPA (2009).
- CalEPA (1997).
- Penn & Snyder (1993), Circulation, 88.
- Bao et al (2023), J Cancer Res Clin Oncol, 149.
- Li et al (2022), Cells, 11.
- Jiang et al (2023), World J Surg Onc, 21.
- Ramnefjell et al (2017), Oncotarget, 8.